Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | DUSP22 | Q9NRW4 | 4/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24487208 | 0.88 | MEN1 (0.78) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL2987796 | 0.85 | MEN1 (0.77) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL26485784 | 0.84 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL26485794 | 0.84 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL10035996 | 0.82 | DUSP22 (0.77) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL9917038 | 0.82 | DUSP22 (0.77) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL12123516 | 0.82 | DUSP22 (0.77) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL20005694 | 0.77 | MEN1 (0.62) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL13220197 | 0.77 | MEN1 (0.62) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL10035969 | 0.76 | MEN1 (0.73) | MEN1KMT2AMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466177-B2 | Treating and preventing viral infections | THE UAB RESEARCH FOUNDATION (US) | 2013-06-18 | — | — | US | disclosed |
| US-20100286212-A1 | Treating and Preventing Viral Infections | THE UAB RESEARCH FOUNDATION (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2217573-A1 | TREATING AND PREVENTING VIRAL INFECTIONS | The UAB Research Foundation (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009059243-A1 | TREATING AND PREVENTING VIRAL INFECTIONS | THE UAB RESEARCH FOUNDATION (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286212-A1 | Treating and Preventing Viral Infections | HAVCR2, IRF3, MAVS | MEN1 3172/4885KMT2A 3809/4885MAPT 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.